Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
| Autor: | Jagasia, Madan 1, 1, Perales, Miguel-Angel 2, 3, Schroeder, Mark A. 4, Ali, Haris 5, Shah, Nirav N. 6, Chen, Yi-Bin 7, Fazal, Salman 8, Dawkins, Fitzroy W. 9, Arbushites, Michael C. 9, Tian, Chuan 9, Connelly-Smith, Laura 10, 11, Howell, Michael D. 9, Khoury, H. Jean 12 |
|---|---|
| Zdroj: | In Blood 14 May 2020 135(20):1739-1749 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|